Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Statin Treatment of Oxysterol Pathology in SPG5
2015-000978-35Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of atorvastatin in Spastic paraplegia 5A (SPG5A), sponsored by University Hospital Tübingen. Primary endpoint: Change in serum 27-hydroxycholesterol level. Started Jun 2015; status: completed.
02
Drugs
atorvastatin
03
Conditions
Spastic paraplegia 5A (SPG5A)
Beyond the preview
Go deeper on 2015-000978-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000978-35.